Cerus (NASDAQ:CERS) Issues Quarterly Earnings Results

Key Points

• Cerus reported a quarterly EPS of ($0.03), falling short of the consensus estimate of ($0.02) by ($0.01).
• The company’s negative return on equity stands at 34.81% with a net margin of 10.23%.
• Institutional investors own 78.37% of Cerus's stock, with significant increases in holdings from firms like AQR Capital Management.

Cerus (NASDAQ:CERS - Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01), Zacks reports. The firm had revenue of $60.10 million during the quarter, compared to the consensus estimate of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus updated its FY 2025 guidance to EPS.

Cerus Stock Performance

Shares of Cerus stock traded down $0.02 during trading hours on Friday, reaching $1.23. 487,632 shares of the stock traded hands, compared to its average volume of 1,310,396. Cerus has a one year low of $1.12 and a one year high of $2.39. The company has a quick ratio of 1.63, a current ratio of 2.00 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $234.17 million, a price-to-earnings ratio of -12.25 and a beta of 1.55. The company has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.46.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd bought a new position in Cerus in the 1st quarter valued at $32,000. Cubist Systematic Strategies LLC increased its holdings in shares of Cerus by 152.4% in the first quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company's stock valued at $145,000 after purchasing an additional 62,854 shares during the period. AQR Capital Management LLC grew its holdings in Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company's stock worth $1,986,000 after acquiring an additional 1,064,133 shares during the period. Finally, Millennium Management LLC grew its holdings in Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock worth $4,479,000 after acquiring an additional 344,395 shares during the period. 78.37% of the stock is owned by hedge funds and other institutional investors.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.